Effects of Methylphenidate and Sulpiride on Brain and Cognition: An exploratory PET, Pharmaco-fMRI Study

• Conditions: Dopamine, cognition, working memory, striatum

• Registration Number: NL-OMON28994
• Lead Sponsor: Donders Institute for Brain, Cognition, and Behaviour, Centre for Cognition, Radboud University Nijmegen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

1. Healthy volunteers;

2. Age 18 - 45 years;

Exclusion Criteria

Diagnosis (or history of) psychiatric treatment (e.g., severe depression, anorexia nervosa, severe mood disorders, mania, schizophrenia or borderline personality disorder) / Diagnosis (or history of) neurological treatment / Diagnosis (or history of) endocrine treatment / Diagnosis (or history of) neuroendocrine treatment (e.g., phechromocytoma, hyperthyroidism, Cushing’s syndrome) / (History of) melanoma / Presence of prolactin-dependent tumors (e.g., pituitary prolactinoma or breast cancer) / (History of) requent autonomic failure (e.g., vasovagal reflex syncope) / (History of) clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, cardiovascular, metabolic, ocular or pulmonary disease/disorders / (History of) epilepsy in adulthood (i.e. no insult after 18 years of age, no current medication for epilepsy and no insult in the last five years) / (History of) drug dependence (opiate, LSD, (meth)amphetamine, cocaine, solvents, or barbiturate) or alcohol dependence / (History of) Raynaud’s syndrome /Hypersensitivity to sulpiride, methylphenidate, entacapone, or sulpiride / One first degree or two or more second degree family members with a history of sudden death or ventricular arrhythmia / Suicidality / History of prescribed medication within the last month prior to the start of the study. / History of ‘over the counter’ medication within the last two months (with exception of occasional use of paracetamol, acetylsalicylic acid, and ibuprofen). / Use of MAO inhibitor, anaesthetic, anti-depressant or anti psychotic drugs within the week prior to the start of the study. / Average use of psychotropic medication or recreational drugs weekly or more. / Cannabis use within 2 weeks prior to the start of the study, and periods of more than 3 months using weekly or more in the last 6 months /Use of psychotropic medication, or of recreational drugs over a period of 72 hours prior to the test sessions, and use of alcohol within the last 24 hours before each measurement. / Average use of more than 3 alcohol beverages daily. / Average use of psychotropic medication or recreational drugs weekly or more. / Habitual smoking, i.e., more than a pack of cigarettes per week a self-reported inability or unease to cease smoking for 24 hours to testing. / Regular use of corticosteroids. / Uncontrolled hypertension, defined as diastolic blood pressure at rest > 95 mmHg or systolic blood pressure at rest > 180 mmHg / Hypotension, defined as diastolic blood pressure < 50 mm Hg or systolic < 95 mm Hg or resting pulse rate < 45 beats/min / Diabetes / Abnormal hearing or (uncorrected) vision. / First degree family member with schizophrenia, bipolar disorder or major depressive disorder

Study & Design

• Study Type: Interventional
• Study Design: Not specified